Parosteal osteosarcomas: Unusual findings

Encinas-Ullán, Carlos A.; Ortiz‐Cruz, Eduardo J.; Barrientos-Ruiz, Irene; Valencia-Mora, M.; Gonzalez-Lopez, J.

doi:10.1016/j.recote.2012.06.001

Cited by 3 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dedifferentiated low-grade osteosarcomas ranged from 1 to 33 in each of the selected papers. Six studies were conducted in Italy, 10 , 12 , 16–19 six in the United States, 20–25 four in Japan, 9 , 26–28 one in each of the following countries: Australia, 29 Austria, 30 Spain, 31 Netherlands, 32 Indonesia, 33 South Korea 34 and one was a multicenter European study. 35 Fourteen were retrospective series and nine were case reports.…”

Section: Resultsmentioning

confidence: 99%

Dedifferentiated Low-Grade Osteosarcoma, Outcome with or Without Chemotherapy: A Systematic Review

Pacheco¹,

Guzmán²,

Bonilla³

2023

ORR

View full text Add to dashboard Cite

The treatment of low-grade osteosarcomas is surgical resection with wide margins. In instances of dedifferentiation, a therapeutic paradigm similar to that of conventional high-grade osteosarcoma has not been adequately evaluated in these neoplasms. The main objective of this review was to define whether the addition of chemotherapy to surgical treatment has an impact on the survival of patients with dedifferentiated low-grade osteosarcomas. Secondary objectives were to observe the degree of histological response to neoadjuvant chemotherapy and to describe the percentage of de novo dedifferentiation. A systematic search of articles including dedifferentiated low-grade osteosarcomas, published between 1980 and 2022 was carried out in the PubMed, Cochrane and Scielo databases. A qualitative synthesis of the results was performed. Twenty-three articles comprising 117 patients were included. The survival of patients treated with surgery alone and surgery with chemotherapy was not statistically significant between the two groups. A good histological response was seen in 20% of specimens treated with neoadjuvant chemotherapy. De novo dedifferentiation was seen in approximately a fifth of low-grade osteosarcomas. The evidence available suggests that the addition of chemotherapy does not have an impact on the survival of patients with low-grade dedifferentiated osteosarcomas.

show abstract

Section: Resultsmentioning

confidence: 99%

Dedifferentiated Low-Grade Osteosarcoma, Outcome with or Without Chemotherapy: A Systematic Review

Pacheco¹,

Guzmán²,

Bonilla³

2023

ORR

View full text Add to dashboard Cite

show abstract

“…2 ). 5 , 14 The most typical location is the posterior surface of the distal femoral metaphysis followed by the proximal tibia, fibula and humerus, whereas involvement of the ulna, tarsal and carpal bones has been sporadically described. Symptoms include a painless mass with duration of at least one year.…”

Section: Parosteal Osteosarcoma (Pao)mentioning

confidence: 99%

“…Symptoms include a painless mass with duration of at least one year. 14 As the mass increases in size, pain worsens. Decreased range of motion might occur if the lesion is adjacent to a joint.…”

Section: Parosteal Osteosarcoma (Pao)mentioning

confidence: 99%

Surface bone sarcomas: an update on current clinicopathological diagnosis and treatment

et al. 2021

View full text Add to dashboard Cite

Surface bone sarcomas are rare malignant bone tumours. Osseous and cartilaginous surface bone sarcomas are the most common, with parosteal and periosteal osteosarcomas, periosteal chondrosarcomas and secondary peripheral chondrosarcomas being the most frequent. Their clinical symptoms are non-specific and include pain for several months, swelling and limited range of motion of the adjacent joints. Prompt diagnosis is important, as biological behaviour, imaging and histopathologic characteristics, treatment and prognosis differ considerably from their conventional intramedullary counterparts. Moreover, their imaging characteristics are not infrequently non-characteristic and may be misinterpreted as juxtacortical benign lesions leading to incorrect diagnosis and treatment, with life-threatening repercussions. Molecular studies and histopathological sampling are essential for accurate diagnosis. There are still numerous issues regarding the biology, pathophysiology and treatment options of these entities due to their rarity. Cite this article: EFORT Open Rev 2021;6:905-917. DOI: 10.1302/2058-5241.6.210064

show abstract

Can imaging distinguish between low-grade and dedifferentiated parosteal osteosarcoma?

Lin

et al. 2018

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

show abstract

Parosteal osteosarcomas: Unusual findings

Cited by 3 publications

References 12 publications

Dedifferentiated Low-Grade Osteosarcoma, Outcome with or Without Chemotherapy: A Systematic Review

Dedifferentiated Low-Grade Osteosarcoma, Outcome with or Without Chemotherapy: A Systematic Review

Surface bone sarcomas: an update on current clinicopathological diagnosis and treatment

Can imaging distinguish between low-grade and dedifferentiated parosteal osteosarcoma?

Contact Info

Product

Resources

About